These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 21851326)

  • 1. Vaccinia and other viruses with available vaccines show marked homology with the HIV-1 envelope glycoprotein: the prospect of using existing vaccines to stem the AIDS pandemic.
    Carter CJ
    Immunopharmacol Immunotoxicol; 2012 Apr; 34(2):222-31. PubMed ID: 21851326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
    Perdiguero B; Gómez CE; Cepeda V; Sánchez-Sampedro L; García-Arriaza J; Mejías-Pérez E; Jiménez V; Sánchez C; Sorzano CÓ; Oliveros JC; Delaloye J; Roger T; Calandra T; Asbach B; Wagner R; Kibler KV; Jacobs BL; Pantaleo G; Esteban M
    J Virol; 2015 Jan; 89(2):970-88. PubMed ID: 25355891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges.
    Khattar SK; Manoharan V; Bhattarai B; LaBranche CC; Montefiori DC; Samal SK
    mBio; 2015 Jul; 6(4):e01005. PubMed ID: 26199332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.
    Perdiguero B; Sánchez-Corzo C; Sorzano COS; Saiz L; Mediavilla P; Esteban M; Gómez CE
    Viruses; 2019 Feb; 11(2):. PubMed ID: 30781504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated viremia in cats vaccinated with recombinant vaccinia virus expressing envelope glycoprotein of feline immunodeficiency virus.
    Osterhaus AD; Tijhaar E; Huisman RC; Huisman W; Darby IH; Francis MJ; Rimmelzwaan GF; Siebelink KH
    AIDS Res Hum Retroviruses; 1996 Mar; 12(5):437-41. PubMed ID: 8882329
    [No Abstract]   [Full Text] [Related]  

  • 6. Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.
    Bridge SH; Sharpe SA; Dennis MJ; Dowall SD; Getty B; Anson DS; Skinner MA; Stewart JP; Blanchard TJ
    Virol J; 2011 Sep; 8():429. PubMed ID: 21899739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.
    Wilson SE; Pedersen SL; Kunich JC; Wilkins VL; Mann DL; Mazzara GP; Tartaglia J; Celum CL; Sheppard HW
    AIDS Res Hum Retroviruses; 1998 Jul; 14(11):925-37. PubMed ID: 9686639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice.
    Jongwe TI; Chapman R; Douglass N; Chetty S; Chege G; Williamson AL
    PLoS One; 2016; 11(7):e0159141. PubMed ID: 27427967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial.
    Hertz T; Logan MG; Rolland M; Magaret CA; Rademeyer C; Fiore-Gartland A; Edlefsen PT; DeCamp A; Ahmed H; Ngandu N; Larsen BB; Frahm N; Marais J; Thebus R; Geraghty D; Hural J; Corey L; Kublin J; Gray G; McElrath MJ; Mullins JI; Gilbert PB; Williamson C
    Vaccine; 2016 Nov; 34(47):5792-5801. PubMed ID: 27756485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients.
    Durali D; Morvan J; Letourneur F; Schmitt D; Guegan N; Dalod M; Saragosti S; Sicard D; Levy JP; Gomard E
    J Virol; 1998 May; 72(5):3547-53. PubMed ID: 9557634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altering an artificial Gagpolnef polyprotein and mode of ENV co-administration affects the immunogenicity of a clade C HIV DNA vaccine.
    Böckl K; Wild J; Bredl S; Kindsmüller K; Köstler J; Wagner R
    PLoS One; 2012; 7(4):e34723. PubMed ID: 22509350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mapping and characterization of visna/maedi virus cytotoxic T-lymphocyte epitopes.
    Wu C; Barbezange C; McConnell I; Blacklaws BA
    J Gen Virol; 2008 Oct; 89(Pt 10):2586-2596. PubMed ID: 18796728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.
    Mothe B; Climent N; Plana M; Rosàs M; Jiménez JL; Muñoz-Fernández MÁ; Puertas MC; Carrillo J; Gonzalez N; León A; Pich J; Arnaiz JA; Gatell JM; Clotet B; Blanco J; Alcamí J; Martinez-Picado J; Alvarez-Fernández C; Sánchez-Palomino S; Guardo AC; Peña J; Benito JM; Rallón N; Gómez CE; Perdiguero B; García-Arriaza J; Esteban M; López Bernaldo de Quirós JC; Brander C; García F;
    J Antimicrob Chemother; 2015; 70(6):1833-42. PubMed ID: 25724985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 env, nef, and gag-specific T-cell immunity in mice: conserved epitopes in nef p27 and gag p25 proteins.
    Michel F; Hoffenbach A; Froussard P; Langlade-Demoyen P; Kaczorek M; Kieny MP; Plata F
    AIDS Res Hum Retroviruses; 1992 Apr; 8(4):469-78. PubMed ID: 1376136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, construction, and characterization of a multigenic modified vaccinia Ankara candidate vaccine against human immunodeficiency virus type 1 subtype C/B'.
    Chen Z; Huang Y; Zhao X; Ba L; Zhang W; Ho DD
    J Acquir Immune Defic Syndr; 2008 Apr; 47(4):412-21. PubMed ID: 18209682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of gag- and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus.
    Flynn JN; Beatty JA; Cannon CA; Stephens EB; Hosie MJ; Neil JC; Jarrett O
    AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1107-13. PubMed ID: 8554908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.
    Fischer W; Perkins S; Theiler J; Bhattacharya T; Yusim K; Funkhouser R; Kuiken C; Haynes B; Letvin NL; Walker BD; Hahn BH; Korber BT
    Nat Med; 2007 Jan; 13(1):100-6. PubMed ID: 17187074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques.
    De Rose R; Batten CJ; Smith MZ; Fernandez CS; Peut V; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Venturi V; Davenport MP; Kent SJ
    J Virol; 2007 Jan; 81(1):292-300. PubMed ID: 17050602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the expression and immunogenicity of poliovirus replicons that encode simian immunodeficiency virus SIVmac239 Gag or envelope SU proteins.
    Anderson MJ; Porter DC; Moldoveanu Z; Fletcher TM; McPherson S; Morrow CD
    AIDS Res Hum Retroviruses; 1997 Jan; 13(1):53-62. PubMed ID: 8989427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with a fusion protein that introduces HIV-1 gag antigen into a multitrimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-gag.
    Gupta S; Termini JM; Raffa FN; Williams CA; Kornbluth RS; Stone GW
    J Virol; 2014 Feb; 88(3):1492-501. PubMed ID: 24227853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.